Table 2 summarizes different clinical trials focused on PI3K/AKT/mTOR pathway inhibitors. In the same meta-analysis it was found that these inhibitors improved overall survival in breast cancer, renal cancer, gastrointestinal cancer, head and neck squamous cell cancer, pancreatic cancer, neuroendocrine tumor and sarcomas. However, this improvement was not statistically significant and did not show any significant effect on the overall survival in other types of cancers [121]. Here, AKT1 is linked to cancer.